AURA Biopharm AS is in the preclinical phase of developing AUR-1001, a first in class pathogenic-tailored drug for the prevention of thrombosis in patients with Antiphospholipid syndrome (APS). In many reports lupus anticoagulant (LAC) and antiphospholipid antibodies (APAb) are reported positive on Covid-19 patients with...
Read MoreAURA Biopharm AS is in the preclinical phase of developing AUR-1001 as a first in class pathogenic-tailored drug for the prevention and treatment of thrombosis in patients with Antiphospholipid syndrome (APS). APS is an autoimmune disease where patients produce antiphospholipid antibodies causing thrombosis. In a recent...
Read MoreUS CORP, A US biotechnology corporation has purchased a majority of the shares in AURA Biopharm AS. AURA Biopharm AS is a Norwegian Biotechnology company founded by a team of international scientists and drug developers. The company has exclusive rights to the product AUR-1001, which is...
Read MoreAURA Biopharm has received a start-up and commercialization grant of NOK 700.000 (≈ 74.000 €) to support activities to develop AUR-1001 for the treatment of APS. Olav Flaten, CEO and Chairman of AURA Biopharm commented: “AURA is very grateful for this generous grant. That will enable us...
Read MoreKedrion biopharma signed a letter of intent (LOI) to express its interest to participate in the development of AUR-1001 for the treatement of antiphospholipid syndrome. AUR-1101 is an anti Beta2 GP1 monoclonal antibody which represents a first-in-class treatment for antiphospolipid syndrome (Hughes syndrome), an autoimmune...
Read MoreAura Biopharm has announced the the US Patent office has granted a patent covering the treatment and prevention of APS with its molecule AUR-1101. The patent US61/844,505 was granted in July 2017. AUR-1101 is an anti Beta2 GP1 monoclonal antibody which represents a first-in-class treatment for...
Read MoreAURA Biopharm AS has entered a partnership with Smerud Medical Research International AS (SMERUD). The agreement describes an alliance which includes co-investment in, and co-development of AUR-1001 in the treatment of Antiphospholipid syndrome. SMERUD is a contract research organization with a dedicated business unit for...
Read MoreAURA Biopharm, Eurocine Vaccines and Ocuspecto have been announced as the winners of Nordic Stars 2016 Awards (http://www.aurabiopharm.com/aura-biopharm-winner-of-the-nordic-star-award-2016-in-stockhol/). The awards were presented at the conclusion of the Nordic Life Science Days (NLSDays) in Stockholm, which again set a new record for attendance. More than 1 070...
Read More